RxDoctor Payments Data

Christopher Fleissner, DO

Family Medicine · Pittsburgh, PANPI 1588827828

Payments from drug & device makers

$1,073in general payments, 2019–2025

Across 65 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$334
  • Johnson & Johnson$206
  • Boehringer Ingelheim$154
  • Lilly USA, LLC$103
  • AstraZeneca$80
  • GSK$79
  • plus $117 from 5 others

What the payments were for

  • Food & beverage$1,05899%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,073 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$53,959
Medicare patients
140
Services billed
565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide223$235,634
EliquisApixaban223$163,249
TrulicityDulaglutide65$97,525
FarxigaDapagliflozin Propanediol34$51,800
JardianceEmpagliflozin51$47,891
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$42,829
XareltoRivaroxaban43$39,806
Breo ElliptaFluticasone/Vilanterol54$21,333
EntrestoSacubitril/Valsartan25$18,857
MounjaroTirzepatide15$15,134
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$14,625
LinzessLinaclotide18$10,755
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$8,408
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,333
Gabapentin334$7,508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$334$235,634223 claims
PfizerEliquis$18$163,249223 claims
Lilly USA, LLCTrulicity, Mounjaro$103$112,65980 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$79$76,471128 claims
Boehringer IngelheimJardiance, Stiolto Respimat$154$56,30067 claims
AstraZenecaFarxiga$80$51,80034 claims
Johnson & JohnsonXarelto$206$39,80643 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →